Former financial leader at Radius Global Infrastructure and Crown Castle will steer finance strategy to meet next stage of enterprise, cloud and AI infrastructure demand

DALLAS, Sept. 22, 2026 — DataBank, a leading provider of enterprise-class colocation, interconnection, and managed services, announced today that Ben Lowe has been appointed Chief Financial Officer (CFO). Lowe will lead all of DataBank’s finance, accounting, treasury, and capital markets functions and will report to DataBank’s President and current CFO, Kevin Ooley, who will be transitioning to CEO on January 1, 2027. DataBank’s current CEO, Raul Martynek, will become Executive Chairman of the Board on January 1, 2027.

Lowe joins DataBank as the company embarks on its next phase of evolution, continuing to provide highly compliant, mission-critical, colocation services to 2,500+ enterprise customers while capitalizing on the rapid growth in digital infrastructure driven by AI and hyperscale cloud demand.  He brings to DataBank a deep reservoir of experience scaling financial operations and capital structures in both public and private equity-backed organizations as well as insight and perspective across the digital infrastructure ecosystem from data centers to wireless networks.  

“Ben possesses a mix of industry knowledge, financial acumen, and capital markets experience that will be incredibly valuable for DataBank as we enter this next chapter,” said Kevin Ooley, DataBank’s President and acting CFO. “His proven ability to access both public and private markets and his track-record of synthesizing capital with strategy will be critical as we navigate this next phase of evolution.”

Most recently, Lowe served as Chief Financial Officer at Radius Global Infrastructure, a portfolio company of EQT Active Core Infrastructure and the Public Sector Pension Investment Board that specializes in the strategic acquisition and management of critical telecommunication infrastructure including cell site leases, network switches/exchanges, fiber aggregation points, Distributed Antenna Systems (DAS), data centers, and towers.  Prior to that, Lowe served as Senior Vice President of Corporate Finance and Treasurer at Crown Castle, an owner and operator of approximately 40,000 wireless towers across the U.S.

“DataBank’s U.S. data center infrastructure footprint is unparalleled, and the company has a rich history of building long-term relationships with customers and capital markets alike,” said Lowe. “This is an incredible platform and track-record upon which to chart the next era of growth and I’m incredibly excited to be joining at such a monumental time.“

“I’m delighted to have Ben joining our leadership team,” added Raul Martynek, DataBank’s CEO. “He and Kevin are the right leaders to champion DataBank’s next phase of growth and continue our heritage of financial strength and performance. I look forward to supporting them in 2027 in my new role as Executive Chairman of the board.”

About DataBank

DataBank helps the world’s largest enterprises, technology, and content providers ensure their data and applications are always on, always secure, always compliant, and ready to scale to meet the needs of the artificial intelligence era.

Recognized by Deloitte in 2023 and 2024, and Inc. 5000 in 2024 as one of the fastest-growing private US companies, DataBank’s edge colocation and infrastructure footprint consists of 70+ “HPC-ready” data centers in 25+ markets, 20 interconnection hubs, and on-ramps to an ecosystem of cloud providers with virtually unlimited reach.

We combine these platforms with contract portability, managed security, compliance enablement, hands-on support, and a guarantee of 100% uptime availability, to give our customers absolute confidence in their IT infrastructure and the power to create a boundless digital future for their business.

To learn more, follow us on LinkedIn or subscribe to our YouTube channel. To tour a facility, visit DataBank or call 1(800) 840-7533.

SOURCE DataBank

Powered by agentic AI, Chamelio’s platform is primed to replace outdated legacy contract lifecycle management systems and empower legal teams to embrace AI-powered operations. Since its seed round five months ago, Chamelio’s ARR has grown 4x

NEW YORK, Sept. 22, 2026 — Chamelio, the AI-native platform for in-house legal teams, today announced a $26 million Series A round led by Entrée Capital, with participation from existing investors Work-Bench and Emerge Ventures. Bright Pixel Capital also participated. Chamelio boasts hundreds of customers, including Wiz, monday.com, Socure, AppsFlyer, and Wonderful.ai. The company will use the new funding to further develop its proprietary legal action model, grow its legal engineering and product teams and invest further in onboarding technology.

In-house legal departments are overworked and understaffed, with workload demands surging, while budgets and headcount are not keeping pace. An Association of Corporate Counsel survey from this year found that budget and resource constraints were a key barrier to success. Meanwhile, only 32% of legal departments expect to add attorney headcount this year, according to CLOC’s 2026 State of the Industry Report. Most in-house legal teams are still relying on legacy Contract Lifecycle Management (CLM) software built to store contracts, not analyze or act on them, with the painstaking additional work falling on the same number of overburdened teams.

The legal sector has adopted AI faster than almost any other profession. Deloitte predicts in three years, 30% of a legal team will be AI agents, and one in five will be hybrid lawyer-engineers. This role bridges the gap between technology and legal expertise. Chamelio enables the legal teams of today to delegate the tedious manual labor of contract review to autonomous agents, laying the groundwork for a completely different in-house composition of the future, consisting of both lawyers and AI agents.

Chamelio is an AI-native legal platform for in-house teams that manages and executes the full contract lifecycle, from drafting and negotiation to approvals, obligations, and ongoing legal workflows. Unlike traditional contract management systems built primarily to store documents and manage processes, Chamelio is trained on legal actions and can perform the work itself. It drafts from a company’s own contracts, reviews and negotiates terms, routes requests, manages obligations, and executes multistep legal workflows. Customers can deploy it autonomously for routine, low-risk work or keep a lawyer in the loop where oversight is needed. By handling routine tasks and decisions independently and escalating only the edge cases that require human judgment, Chamelio shifts the in-house lawyer’s role from labor-intensive execution to strategic oversight and judgment.

Chamelio also allows legal teams to easily build their own agents which support and interact with multiple functions across the organization, from procurement to finance, product to people, compliance to sales, helping scale and amplify legal capabilities for enterprise in the AI era.

“The mistake in legal AI has been assuming the future simply looks like today’s lawyer with faster contractual fact-checking,” said Alex Zilberman, CEO and co-founder of Chamelio. “AI in a legal setting shows dividends when it can make decisions intuitively, built on the corporate intelligence of each individual business. This is what Chamelio does. We ensure in-house legal departments deliver watertight contracts and outputs at AI speed, validated by the rigor of lawyers.”

“Chamelio is building the AI-native operating system for in-house legal teams – becoming the system of record, system of action, and system of intelligence for the modern legal function,” said Eran Bielski, General Partner at Entrée Capital. “What stood out to us was not only the strength of the product, but how quickly Chamelio’s founders execute, learn from customer feedback, and turn that feedback into a product with category-defining potential.”

Chamelio’s platform integrates with CRMs like Salesforce, as well as other tools such as Slack, NetSuite and procurement systems. Every deployment from Chamelio’s platform contains access to dedicated legal engineering expertise that helps customers migrate from legacy systems, structure their repositories, translate existing processes into workflows and get AI into production quickly.

Zilberman added: “Chamelio is empowering the next era of legal operations, one which includes vital human legal judgment, backed by legal engineers who turn that knowledge into systems and AI agents. With our platform underpinning every facet of in-house contract execution, we are redefining how in-house legal activities are carried out.”

About Chamelio

Founded in 2024 by serial entrepreneurs and two-time founders, Alex Zilberman and Gal Lellouche, alongside former general counsel, Gil Banyas, Chamelio is the AI system of action for in-house legal teams. Its platform combines contract negotiation, legal intake, workflows, contract intelligence and knowledge in one platform. Its software, AI-powered migration technology and legal engineering model helps corporate legal departments move from legacy systems to AI that does the work.

Media Contact

Headline Media
Jack Mendel – [email protected]

SOURCE Chamelio

Funding accelerates R&D and retail expansion as Bird&Be fills gaps in fertility care.

TORONTO, Sept. 22, 2026 — Bird&Be, the fertility and wellness brand making supplements and at-home tests for women and men at every stage of the fertility journey, today announced $13M in funding to fuel product development, retail expansion, and access to trusted, evidence-based reproductive health support – whether someone is trying to conceive, managing a condition like PMOS, supporting a pregnancy, or simply taking a proactive first step in understanding their fertility. The round is led by BDC Thrive, BFG Partners, and supported by BAM Ventures, Founder Collective, Rejuvenation Ventures, and HSR Ventures.

Why the fertility category needs a trusted intervention:

• 1 in 6 people experience infertility, and up to 50% of cases involve male factors; yet fewer than 1,400 fertility specialists (REIs) practice nationwide, and nearly half of U.S. counties lack an OB-GYN.
• PMOS affects 1 in 10 women but can take many years to diagnose, leaving an estimated 70% of women undiagnosed and unsupported in managing their cycles and fertility.
• Prenatal vitamins need a higher standard too: a recent Consumer Reports investigation found nearly all (15 of 17) prenatal vitamins tested contained more or less of key nutrients than their labels claimed, including folic acid, which is essential for neural tube development. Bird&Be’s Prenatal met all of its label claims in Consumer Reports’ evaluation. Note: Consumer Reports does not endorse products or services.

With third-party-tested supplements formulated and backed by OB-GYNS, REIs, and naturopathic fertility specialists, Bird&Be steps in to give women and men the nutritional support they need for healthy conception, pregnancies, and postpartum recovery. They are also the only brand to offer at-home diagnostic tests alongside supplements –  Sperm Test Kits and Ovarian Reserve Screening Tests for under $100 – giving couples the tools to take proactive care of their reproductive health to improve outcomes.

In its first three years, Bird&Be grew to an eight-figure brand with nearly 100% year-over-year growth and 75% of revenue coming from subscriptions. The brand has grown its clinician-referral channel 200% year-over-year — with more than 10% of customers now coming through a healthcare provider recommendation. Bird&Be launched in 300 Ulta Beauty stores in September 2025 and expanded to nearly 1,000 stores by spring 2026, becoming the first fertility brand to place male and female products side by side in a national beauty retailer. Bird&Be recently partnered with Mandell’s Clinical Pharmacy to extend its reach directly to patients navigating fertility treatment in all 50 states.

The new funding will fuel research and clinical studies, product development, continued retail expansion, and the growth of Bird&Be’s clinical distribution channel.

“We started Bird&Be because my Co-Founder Breanna Hughes and I didn’t have the support we needed navigating PMOS and pregnancy loss ourselves,” said Samantha Diamond, Bird&Be Co-Founder and CEO. “We get it because we lived it. Every product we make helps our customers and community feel educated and in control. We intentionally created a brand that would bring men into the fertility narrative as well, giving them the supplements and tools to care for their own reproductive health and grow their families. We’ve been able to support hundreds of thousands of people in their fertility journeys over the past few years and the new funding helps us make trusted products even more accessible when and where people need care most.”

“Bird&Be is building a category-defining company at the intersection of women’s health, consumer health, and preventative care,” said Mona Minhas, Managing Partner, BDC Thrive Venture Fund. “By combining science-backed products with accessible education, Bird&Be is addressing a significant unmet need in a large and underserved market. We’re excited to lead this investment and partner with the team as they scale their impact. Supporting exceptional women-led companies like Bird&Be is central to Thrive’s mandate and to BDC’s commitment to fueling innovation and economic growth in Canada.”

“Bird&Be pairs a deep body of fertility science with a product experience people actually stick with. That combination is rare,” said Elizabeth Earle, Vice President at BFG. “BFG strongly believes that brands built on real transparency, like Bird&Be, should be within reach of more people and we’re eager to support Samantha and Breanna’s mission in bringing them to women and men hoping to build their families.”

About Bird&Be

Bird&Be is a fertility and wellness brand providing supplements and at-home tests for both partners at every stage of the fertility journey. Formulated by fertility doctors, OB-GYNs, and naturopathic specialists, Bird&Be offers prenatal, pregnancy, postpartum, and hormone-supporting supplements with therapeutic, bioavailable, third-party-tested ingredients. Bird&Be products are available on birdandbe.com, in Ulta stores and online, and through clinical partnerships like Mandell’s Clinical Pharmacy. Learn more at birdandbe.com 

SOURCE Bird&Be

SAN DIEGO, Sept. 22, 2026 — Primrose Bio, Inc. (“Primrose”), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners (“Signet”), with significant participation from existing investors 1315 Capital, Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), LDV Partners, and Agent Capital. In conjunction with the financing, James Gale, Founding Partner and Managing Director of Signet, has joined Primrose’s Board of Directors.

The proceeds will help Primrose continue to expand the reach and capabilities of its differentiated technology portfolio:

• Pfenex Expression Technology^® (“Pfenex”), a scalable microbial expression platform for efficient, high-yield production of complex, engineered proteins used in six approved biologics
• Prima RNApols^®, proprietary RNA polymerases for consistent, scalable, high-quality mRNA manufacturing (available in RUO- and GMP-grade)
• PeliCRM197^®, a validated carrier protein used in multiple approved vaccines (RUO and GMP) 

“This financing marks an important next step for Primrose and reflects confidence in our technologies, team and commercial opportunity,” said Andrew Burch, Chief Executive Officer of Primrose Bio. “As the engineering of biologic and nucleic acid medicines advances, developers need more robust production systems that also improve quality, yield, speed, scalability and cost. This capital will help us broaden adoption, enhance capabilities and accelerate customers moving therapeutic and vaccine programs forward toward clinical trials.” 

“Signet sees a compelling opportunity across Primrose’s portfolio,” said James Gale. “Having partnered with The Dow Chemical Company to establish Pfenex Inc. in 2009, we have seen the platform’s commercial value firsthand. Primrose is building on that foundation with further advances in Pfenex technology as well as Prima RNApols and PeliCRM197. We are pleased to invest in this next phase of growth and support the team as they scale the business and help more customers improve manufacturing performance across multiple therapeutic modalities.”

About Primrose Bio, Inc.

Primrose Bio develops and commercializes manufacturing technologies that close gaps in biologics, mRNA and vaccine production. Primrose’s major offerings include Pfenex Expression Technology^®: a proprietary microbial production system used in six approved products with up to 20x higher yields and a strong record across diverse protein modalities; Prima RNApols^®: improved enzymes for mRNA manufacturing; and PeliCRM197^®: a commercially validated CRM197 carrier protein used for conjugate vaccines.  Several of the world’s leading pharmaceutical companies use Primrose’s technologies in marketed products, including Merck, Jazz Pharmaceuticals, Alvogen, and Serum Institute of India. For more information, please visit: www.primrosebio.com.

About Signet Healthcare Partners

Signet Healthcare Partners is a healthcare growth equity firm that invests in commercial-stage pharmaceutical (pharma services and therapeutics) and medical technology companies. Founded in 1998 and based in New York, Signet has invested in more than 60 companies, supporting entrepreneurs with capital, strategic guidance, and deep industry networks. For more information, please visit: www.signethealthcarepartners.com.

SOURCE Primrose Bio

Left Lane Capital incubated and led the round as Rising Tide scales property management firms with shared technology and capital, without asking them to give up their name, team, or local relationships

CHICAGO, Sept. 22, 2026 — Rising Tide, which acquires and invests in independently owned residential property management companies, today announced the close of an undisclosed seed round led by Left Lane Capital. Left Lane incubated the company alongside CEO Blake Mohseni on a shared conviction: property management is a large and deeply fragmented market; it is mission-critical to the lives of everyday consumers, and its complexity across multiple stakeholders creates unique opportunities for AI to improve the customer experience.

Property management is a $100B+ market split across more than 240,000 property management firms that together handle a large share of residential rentals. Most run without the technology, systems, and back-office support that larger, well-capitalized platforms take for granted. The result: owners spend more time on manual admin than on building the tenant and owner relationships that actually differentiate a good property manager. Many also face a tough choice when it comes time to sell or transition: sell to a private equity firm that rebrands them under a national name, or figure out succession alone.

“AI is changing the definition of what premier service looks like in property management. It gives our operators more room for the relationships with owners and tenants that actually built their business,” said Blake Mohseni, Founder and CEO of Rising Tide. “This funding brings that same approach to more independent property management firms: real technology, real capital, and partnership instead of a takeover.”

Rising Tide takes a different approach: a federation of independent property management companies. Each one gets shared technology and capital to grow, while the local brand, the team, and the relationships an owner spent years building remain exactly as they are.

There’s no shortage of AI hype in property management right now. The hard part is knowing how to actually put it to work. That’s where Rising Tide comes in, through The Lab, where the company builds and tests its AI tools inside real property management businesses through hands-on implementation at no cost. The Lab is live today with three property management firms. Rising Tide keeps ownership of what it builds; the operators get full use of it for free, and their business data never leaves their hands.

Vinny Pujji, Co-founder and Managing Partner of Left Lane Capital, said, “We have invested over $100 million into AI companies transforming traditional services industries, from accounting to dental. Property management is universal, mission-critical, and not for the faint of heart. Blake and his team have the thoughtful approach needed to bring AI to the industry and drive modernization alongside tenured operators.”

About Rising Tide

Rising Tide is building a federation of independent property management companies with real capital and technology behind each one, while the local brand, team, and relationships are fully intact. Learn more at www.risingtidehq.com.

About Left Lane Capital

Founded in 2019, Left Lane Capital is a New York and London based venture capital and growth equity firm investing in high growth internet and consumer technology businesses globally. Left Lane’s mission is to partner with extraordinary entrepreneurs who create category defining companies across growth sectors of the economy. For more information, visit www.leftlane.com.

SOURCE Rising Tide

Round Led by .406 Ventures Fuels Teal Health’s Next Phase of Growth, Expanding Payor, Health System, Employer and Provider Partnerships Ahead of Broad Insurance Coverage in 2027

SAN FRANCISCO, Sept. 22, 2026 — Teal Health, creators of the Teal Wand™, the first and most accurate FDA-authorized self-collection device for at-home HPV cervical cancer screening, today announced $22 million in Series A funding to meet accelerating consumer demand and expand access ahead of broad insurance coverage beginning in January 2027.

The round was led by .406 Ventures, with continued backing from Emerson Collective (managed by Yosemite), Forerunner, and Serena Ventures, and new participation from Japan-based MPower Partners. The financing brings Teal Health’s total funding to $45 million. It arrives at a critical moment where nearly one in three U.S. women isn’t up to date on screening, largely due to physician shortages causing limited appointment availability and therefore making the traditional in-office screening difficult to access. Increasing preventive care options for women is a national imperative. As the first to deliver an accurate, convenient at-home screening alternative, Teal is already defining the future of women’s preventive health, ahead of January 2027 federal guidelines that will require most health plans to cover self-collection for cervical cancer screening.

The new capital will fuel a growing network of payor, health system, employer, provider, and brand partnerships that make screening available wherever women receive care, access benefits, or make decisions about their health. Teal Health is also expanding direct-purchase options for individuals and organizations. Together, these channels are designed to move at-home screening beyond early adoption and establish it as a routine, widely available, and highly preferred part of preventive care nationwide. The funding will also support continued hiring across key clinical, commercial, technology, and operational functions as Teal scales to serve more women and partners.

“We designed Teal for all women, whether they are behind on their screening or coming due. Screening is just too difficult today, whether that is finding an appointment, the time in your day to attend, or the physical discomfort. Women need an accurate, trusted alternative that makes it easy to screen,” said Kara Egan, CEO and Co-Founder of Teal Health. “This funding allows us to scale to meet the demand of patients and providers. It’s clear this option is preferred by women and now we can ensure everyone has a way to stay healthy.”

The Teal Wand is the first FDA-authorized self-collection device for at-home HPV cervical cancer screening – no speculum or in-office visit required. Teal Health pairs a private, speculum-free at-home sample collection with a telehealth visit, delivers results through a secure platform, and connects patients to follow-up care when it’s needed. Women love having this option, and Teal data shows 59% of women who choose Teal are underscreened; these are women who now have an option to take care of their health. Thousands of women have rated the end-to-end experience an average of 4.95 out of 5, clear evidence that this is the kind of screening experience women have been waiting for.

“Patients are demanding more convenient ways to access healthcare, and Teal has proven that convenience doesn’t have to come at the expense of accuracy,” said Kathryn Taylor Reddy, Partner at .406 Ventures. “With insurance coverage expanding in 2027, Teal Health is positioned to transform how millions of women receive essential preventive healthcare.”

Since receiving FDA-authorization in 2025, Teal Health has already screened thousands of women nationally, been incorporated in national screening guidelines, advanced research on self-collection screening with 17 peer-reviewed papers and presentations, and is partnering with health systems, providers, employers, and payers – providing access to the Teal Wand where women already receive care – closing screening gaps, easing the load on clinics, and reaching the women who are overdue. Cervical cancer is one of the most preventable cancers, yet thousands of women in the U.S. are diagnosed each year – and roughly 4,320 will die from it this year. This funding extends these partnerships and opens new ways for organizations and individuals to offer screening directly, pushing at-home screening from early-adopter territory into routine care.

To learn more, visit www.getteal.com.

About Teal Health

Teal Health is a women’s health company on a mission to eliminate cervical cancer by making screening accessible, comfortable, and accurate. Its flagship product, the Teal Wand, is the first FDA-authorized at-home HPV self-collection device for cervical cancer screening. Through its telehealth platform, Teal Health provides an end-to-end screening experience that includes access to providers, at-home sample collection, secure results, and support with follow up care. As a member of the Cervical Cancer Roundtable (a collaboration between the American Cancer Society and Cancer Moonshot), Teal Health is helping to shape the future of preventive care. The company continuously advances screening standards through robust clinical evidence, including 17 peer-reviewed papers and presentations. Learn more at getteal.com.

SOURCE Teal Health

Strong participation from existing shareholders and strategic investors drives raise beyond the $10 million target

SCOTTSDALE, Ariz., Sept. 22, 2026 — Monetary Metals®, the global Gold Yield Marketplace^® platform, raised $10.5 million through its latest equity financing, surpassing the initial $10 million target.

The new capital will support the continued development of the Monetary Metals Gold Yield Marketplace®. The company is on an exponential growth trajectory, having more than doubled the amount of gold deployed year over year, and was recently named to the top 8% of the prestigious 2026 Inc. 5000 list.

Founded in 2012 by economist and entrepreneur Keith Weiner, Monetary Metals enables gold owners to earn a yield on their gold, challenging the traditional view that gold is an unproductive asset. The yield is achieved by leasing gold to precious metals businesses such as jewelers and refiners, to finance their gold inventory.

This equity raise includes investment from both existing and new shareholders. The latest financing brings the total amount raised by Monetary Metals to nearly $25 million.

Keith Weiner, founder and CEO of Monetary Metals said: 

“The continued support we receive from investors reflects growing recognition that we have not only created a new category of gold ownership—gold fixed income—but that we are the leader in that category. Because of Monetary Metals, gold is a productive, income-generating asset for clients across the globe. We are seeing strong growth across both sides of our marketplace, from gold owners seeking gold-denominated yield to precious metals businesses accessing more efficient financing solutions than those offered by traditional banks. We are grateful to our investors for supporting our vision of unlocking the productivity of gold and for their continued confidence in our mission as we scale the platform and expand its reach.”

Media Contacts:

About Monetary Metals:

Monetary Metals® is Unlocking the Productivity of Gold™ by offering a Yield on Gold, Paid in Gold® to investors, and Gold Financing, Simplified™ to gold-using businesses (mints, miners, refiners, jewelers, etc.).

Since 2016, individuals and institutions around the world have been earning a yield in gold and silver every month through our Gold Yield Marketplace®.

SOURCE Monetary Metals & Co.

Atum raises $13.5m to build the world’s first open payments network.

SAN FRANCISCO, Sept. 22, 2026 — Atum today emerged from stealth having built the open payments network, a first of its kind, for global money movement. Atum connects payment companies, developers, and enterprises through a single coordination layer, without issuing a currency, operating a blockchain, favoring a rail, or taking custody of customer funds. The company is launching with $13.5 million of funding from Variant, PayPal Ventures, Abstract Ventures, Road Capital, Mirana Ventures, First Commit, Credibly Neutral, and strategic advisor Charlie Songhurst.

Payments are fragmented across currencies, chains, apps, and local rails that do not interoperate, and every handoff adds cost, delay, and complexity. Stablecoins offer fast, low-cost global rails, but are spread across many blockchains, which pushes that complexity onto users. Atum is the coordination layer between them. Any integrator, developer, or application can submit a payment request, while settlement providers compete to fulfill the payments across any supported chain and stablecoin, with native authorization, reversible payments, and identity. Senders specify what they will send; receivers get what they asked to receive.

Atum is incentivized only by volume, and connects participants through a marketplace where settlement providers compete to fulfill each payment. That structure is what makes the network credibly neutral: its interests are aligned with everyone building on it. It is an open-loop payments and commerce platform.

The network serves businesses moving money: card issuers and acquirers, payment service providers, card networks, stablecoin orchestrators, wallets, fintechs, and enterprises—plus developers building on top. Atum supports financial institutions and stablecoin card issuers, for both non-agentic stablecoin payments and agentic payments through agentic protocols including x402 and MPP. Both humans and agents are completing payments on Atum today.

“This is my life’s work,” said Pete Cooling, founder and CEO of Atum. “In 2014 I saw that blockchains were payments networks, and everything since has pointed to the same conclusion. Onchain accounts are the future bank accounts, and new infrastructure is needed to make money move more seamlessly than it does today. Atum is that infrastructure.”

Cooling formerly led the crypto product team at Visa and has been researching and building blockchain-based payments systems over the past decade. He served as Visa’s representative on Linux’s OpenWallet Foundation, helping guide standards for digital wallets across identity, financial accounts, payment cards, and stablecoins.

Atum is open to builders today in at atum.xyz

About Atum

Atum is the open payments network for global money movement. Atum connects payment companies, developers, and enterprises through a unified coordination layer that handles authorization, routing, and confirmation without being a counterparty and without taking custody. Atum issues no currency, runs no blockchain, favors no rail, and doesn’t compete with any participant on its network. Learn more at atum.xyz.

Media Contact: Amy Van Aarle, 1-617-935-5837, [email protected] 

SOURCE Atum

BOSTON, Sept. 22, 2026 — Creatio, an AI CRM and workflow platform where people and AI agents work together, today announced a $300 million investment from 2026 through 2028 in Creatio Bank.AI, its market-leading offering for banks and financial institutions.

The investment comes as financial institutions rapidly accelerate their adoption of AI, and demand for Creatio’s platform continues to grow — Creatio’s financial services vertical grew 48% YoY. The $300 million commitment will build on this momentum, accelerating product AI innovation while expanding the enablement and deployment capabilities, and partner ecosystem needed to drive AI adoption at scale across financial institutions.

With deep experience in financial services, Creatio has built long-standing relationships with leading organizations including Nasdaq, First National Bank of Pennsylvania, Metro Bank, MetLife, CEC Bank, OTP Bank, National Bank of Panama, ESL Credit Union, and many others.

“The next generation of banking will be built around people and AI agents working together across customer and operational workflows,” said Katherine Kostereva, CEO of Creatio. “Our $300 million investment in Creatio Bank.AI will accelerate this transition, giving financial institutions the technology, industry expertise, and partner ecosystem to adopt AI faster and at enterprise scale.”

$300 Million Investment to Accelerate Innovation and Adoption
Between now and 2028, Creatio will significantly increase investment across the following strategic areas:

1. Product and AI innovation
Creatio will further accelerate the development of its Creatio Bank.AI platform, combining the market-leading AI platform, best-in-class AI CRM, and pre-built banking agents.

The platform powers three core banking domains: Growth, Service, and Operations. Growth agents accelerate customer acquisition, onboarding, and share-of-wallet expansion. Service agents elevate customer experience with faster, more personalized resolution. Operations agents streamline compliance, regulatory reporting, and mid- and back-office work.

Creatio will continue to advance its already superior AI Studio, enhancing no-code designers for both personal and enterprise AI agents, centralized AI governance, integrations, AI modality management, security, and enterprise-grade observability.

2. AI adoption and enablement
Creatio is reinforcing its investment in AI adoption and enablement for customers and partners. The focus is on equipping the banking community with the knowledge, frameworks, and hands-on guidance to adopt AI at scale.

The investment expands AI activation programs for customers and partners: dedicated training programs, AI accelerator workshops, and industry-specific guidance. Creatio is also strengthening its global channel delivery capabilities, arming implementation partners with the expertise to help financial institutions deploy high-value AI use cases.

Removing the Limits to AI Adoption in Banking
The investment builds on Creatio’s Unlimited Enterprise vision, enabling people and AI agents to work together on a single platform without traditional constraints around users, agents, workflows, applications, or scale.

As part of this broader commitment to the banking community, Creatio recently launched the Bank.AI hub, a dedicated destination for financial services executives to navigate the AI era. On September 24, Creatio will also host “Bank.AI: Practical AI Use Cases for Banking” digital event, and on October 27, the Bank.AI Summit in Chicago, bringing together industry leaders to share best practices for AI adoption and transformation.

About Creatio

Creatio is an AI CRM and workflow platform where people and AI agents work together — with no limits on users, agents, or scale. We help midsize and large organizations run customer workflows in the AI era. Headquartered in Boston, MA, with a global team and a large ecosystem of partners, Creatio serves thousands of customers in over 100 countries and automates tens of millions of workflows daily. Genuine care for our clients and partners is at the heart of our DNA.

Media Contact
Judyta Krylova
+1 617 765 7997
[email protected]

SOURCE Creatio